Human paraoxonase1 (hPON1) is a potential therapeutic against the toxicity of organophosphorus (OP) pesticides and chemical warfare nerve agents. We tested whether PON1 gene transfer using adenovirus provides protection against the toxicity of the OP diazoxon. Using an adenovirus construct containing hPON1 gene, we showed elevated levels of recombinant hPON1 in vitro in 293A cells and in vivo in mice. The recombinant enzyme was secreted by 293A cells into culture medium and into the systemic circulation of mice. Western blotting revealed that the virally expressed hPON1 had the expected molecular weight of 45 kDa. Recombinant hPON1 in mice was in complex with mouse high-density lipoprotein (HDL) and migrated more slowly than endogenous hPON1 in the human HDL complex. Mice injected with adenovirus expressed PON1 at 600-3480 U ml -1 on day 5 post-treatment, which is 8-50-fold above endogenous. Six mice expressing hPON1 survived 2LD 50 doses of diazoxon. Four of the six mice survived a second dose of diazoxon (for a total of 4LD 50 ) administered 24 h later. In contrast, none of the three mice in the control group survived one 2LD 50 dose. These results show that hPON1 in mice functions as a prophylactic and offers significant protection against lethal doses of diazoxon.
INTRODUCTION
Organophosphorus (OP) compounds, used worldwide as crop saving insecticides or as weapons of chemical warfare nerve agents, pose a substantial threat to soldiers and civilians alike irrespective of whether the nature of their misuse is hostile, terroristic, deliberate, accidental or intentional. 1,2 OP agents inactivate serine hydrolases acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). 3 The acute toxicity 4 and the characteristic symptoms of OP poisoning are attributable primarily to inactivation of AChE, the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. Sustained levels of acetylcholine at cholinergic synapses produce an acute cholinergic crisis characterized by miosis, increased tracheobronchial and salivary secretions, bronchoconstriction, bradycardia, fasciculation, behavioral incapacitation, muscular weakness and convulsions culminating in death by respiratory failure. 5 Current antidotal regimens for OP poisoning include anticholinergic drugs such as atropine sulfate to counteract the effects of elevated acetylcholine, oximes such as 2-PAM chloride to reactivate AChE and anticonvulsants such as diazepam to control OP-induced symptoms of tremors and convulsions. 6 These regimens are successful in preventing lethality due to OP poisoning, but are unable to prevent post-exposure incapacitation, convulsions, performance deficits or, in many cases, permanent brain damage. 7 These treatments have undesirable side effects and require administration within a prescribed time frame for maximal efficacy. The approved oximes have limited efficacy against chemical warfare nerve agent such as soman. Hence, a pre-treatment regimen, especially for military personnel in potential OP exposure scenarios would prove to be advantageous.
The short-acting carbamates, pyridostigmine and physostigmine, are the current choice of pre-treatment to bind targets on AChE preventing irreversible inactivation by OP. An alternate approach is the development of human proteins as bioscavengers that sequester OP before they reach and inhibit AChE. 8, 9 Stoichiometric bioscavengers are the first generation prophylactics. Currently, plasma-derived human BChE [9] [10] [11] and Protexia, a recombinant BChE produced in the milk of transgenic goats, are under investigation. 12, 13 BChE is a stoichiometric bioscavenger, requiring large quantities (200 mg per 70 kg person) of the enzyme to provide protection against 2LD 50 of soman. 14 More recently, enzymes that can inactivate OP without being consumed are being investigated for their potential as catalytic bioscavengers. 15 An ideal candidate would be a stable, non-immunogenic or minimally immunogenic, non-toxic enzyme with a long halflife in the circulation that has high catalytic efficiency for OP hydrolysis. 16 Human paraoxonase1 (hPON1) has the potential to become such a candidate. In particular, the PON1 Q192 isoform is most promising, as it was found to hydrolyze nerve agents sarin and soman more rapidly than the PON1 R192 allele. 17 The hPON1 (EC 3.1.8.1; formerly EC 3.1.1.2) is a calcium-dependent glycoprotein, 354 amino acids in length with an estimated molecular mass of 45 kDa. 18, 19 Carbohydrate structures account for 15% of its molecular mass. 19, 20 A number of studies have provided evidence that PON1 decreases the toxicity of certain OP agents in vivo. 21, 22 PON1 knockout mice were found to be more sensitive to chlorpyrifos and diazinon 23 than control mice, suggesting the ability of PON1 to metabolize these toxic compounds in vivo. In addition, adenoviral vectors containing the gene for PON1 increased serum PON1 activity about 60% and protected mice against the toxicity of chlorpyrifos. 24 However, the usefulness of PON1 in alleviating the toxicity of a nerve agent, such as soman, sarin or VX, remains to be examined.
To overcome the technical challenges associated with testing native or recombinant enzymes for in vivo efficacy studies, gene delivery using viral vectors such as adenovirus is an attractive approach that has been adopted widely. 25 Using high titer adenovirus-expressing human PON1Q192 alloform (hereafter referred to as hPON1), we show persistent and elevated levels of recombinant hPON1 in vitro in HEK-293A cells and in vivo in mice. Mice that have 8-10 times the endogenous level of PON1 activity are protected from the lethality of diazoxon.
RESULTS

Expression and dose response of adenovirus-expressing hPON1 in HEK-293A cells
The ability of adenovirus-expressing hPON1 (Ad-hPON1) to express recombinant hPON1 was evaluated in HEK-293A cells. Media from cells infected with various levels of Ad-hPON1 (0-50 plaque-forming units (pfu) per cell) were assayed for PON1. As shown in Figures 1a (phenylacetate substrate) and 1b (paraoxon substrate), PON1 was detected in the culture media and increased both with incremental levels of virus and time post-infection. Maximal enzyme activity was obtained using 25-50 pfu per cell on 4-5 days post-infection. No further increase in activity was obtained by increasing the virus beyond 50 pfu per cell (data not shown). A quantitative determination of recombinant hPON1 activity in the cell culture medium and cytosolic fractions on day 5 post-virus infection revealed that 95% of the PON1 activity was in the medium and only 5% was within the cytosol (data not shown).
PON1 expressed by 293A cells was partially purified using ammonium sulfate fractionation and metal-affinity chromatography. Partially purified hPON1 was detected on a western blot with anti6Âhistidine antibody. The results shown in Figure 2 suggest that the recombinant hPON1 has a molecular weight B45 kDa and thus appears to be full length and intact. These results suggest that hPON1 was synthesized and secreted by HEK-293A cells in full-length form with the appropriate number of carbohydrate structures.
Recombinant hPON1 protein expressed in mouse plasma
The Ad-hPON1 was introduced into mice by a single injection via the tail vein. The expression of active recombinant hPON1 enzyme was determined in plasma over a period of 10 days. The activity profiles of PON1 using phenylacetate and paraoxon as substrates are depicted in Figure 3 . Each time point in the figure represents mean ± s.e. of values from 6 to 8 mice. The plasma enzyme activities begin to rise rapidly by day 1, reaching peak levels on days 3 to 5 and then declining back to baseline by day 10. The PON1 activity in one mouse increased 50-fold above baseline levels on day 3. This mouse was included in Figure 3 . Overall, 8-50-fold increases in PON1 activity levels (613-3480 U ml -1 ) were achieved over the baseline PON activity (70-120 U ml -1 ) on days 3 to 5 following Ad-hPON1 injection. Importantly, mice tolerated increased levels of hPON1 over extended periods with no overt symptoms of toxicity observed. These results show that a single injection of Ad-hPON1 was capable of introducing high levels of enzymatically active recombinant hPON1 into systemic circulation of mice and that these levels of hPON1 appear to be non-toxic.
Recombinant hPON1 protein expression in mouse tissues
On day 4 post-injection, at the peak of PON1 plasma activity, two Ad-hPON1 mice and one Ad-control mouse were euthanized for A majority of recombinant hPON1 was found in the elution fractions 3 and 4 (lanes 7 and 8) and its molecular size was estimated to be 45 kDa.
determination of PON1 tissue activity. Activity was determined using phenylacetate as the substrate. The two Ad-hPON1-injected mice had plasma levels 7-and 15-fold higher than those in the control mouse (Table 1 ). In contrast, activity levels of PON1 in all the tissues examined of Ad-hPON1-injected mice were similar to those in control virus-injected mouse. These results suggest that the recombinant hPON1 transduced through adenovirus was found primarily in the systemic circulation.
Size of hPON1 expressed in mouse plasma
To determine if the virus-expressed recombinant hPON1 was full length and intact, plasma from the mouse expressing recombinant hPON1 at 3482 U ml -1 on day 3 was analyzed by western blotting with rabbit polyclonal anti-hPON1 peptide antibodies. The antibody recognized a doublet of B45 and B42 kDa in all the samples analyzed (days 1 through 7) (Figure 3 inset) . The lower migrating form likely represents incompletely glycosylated hPON1 as such a phenomenon is well known at very high expression levels of glycoproteins. 26, 27 Plasma from pre-injection bleed (day 0) did not contain detectable amounts of hPON1 protein. The antibody does not appear to cross-react with mouse PON1. Also notable is that despite the very high levels introduced into circulation. no proteolysis was observed. The results in Figure 3 also show correlation of PON1 activity with PON1 protein bands. The activity levels are in excellent agreement with the density of bands on the gel. These results show that recombinant hPON1 expressed in mice is full length and intact and that it remains in an intact form in the circulation as long as 7 days.
Analysis of PON1enzyme activity in mouse plasma by non-denaturing polyacrylamide gel electrophoresis As native PON1 associates with high-density lipoprotein (HDL) in vivo, we analyzed recombinant hPON1 in mouse plasma by nondenaturing polyacrylamide gel electrophoresis (PAGE) to identify if the overexpressed hPON1 is capable of associating with mouse HDL. We chose mouse plasma containing a high level of recombinant hPON1 (3482 U ml -1 on day 3 post-virus injection). The esterase activity in gels was identified by staining with b-naphthylacetate and Fast blue RR ( Figure 4a ). The b-naphthylacetate detects not only PON1, but also BChE, carboxylesterase (CES) and albumin (ALB) esterase. BChE is the weak band near the top of lane 1. CES is the intense band that migrates just above ALB in lanes 2 and 3. ALB is the weak band in lane 1. PON1 is the broad, heavily stained band in lane 3, and the broad fuzzy band in lanes 1 and 2. Positive identification of the PON1 band was obtained by preincubating the gel with 10 mM EDTA, a specific inhibitor of PON1. Figure 3 PON1enzyme activity on various days in plasma of mice injected with Ad-hPON1 (n¼8). Blood samples from mice were collected on days 0 to 11 before and after Ad-hPON1 injection. Plasma samples were analyzed for PON1 activity with the substrates phenylacetate (black bars) and paraoxon (white bars) as described in Materials and methods. One unit of PON1 activity is defined as 1 mmol phenylacetate or 1 nmol paraoxon hydrolyzed per min under standard assay conditions. Activities plotted were mean ± s.e. Inset: Expression and secretion of hPON1 in mouse serum as a function of time. Plasma samples from a mouse that showed maximal expression of hPON1 were analyzed by sodium dodecyl sulfate (SDS)-PAGE followed by western blotting using anti-hPON1 polyclonal antibodies. Table 1 Distribution of human PON1 activity determined using phenylacetate as the substrate in tissues and plasma on day 4 following Ad-hPON1 IV injection into two mice and one control mouse Abbreviations: Ad-hPON1, adenovirus-expressing hPON1; hPON1, human paraoxonase1. Control mice received the Ad-control virus in the same manner as Ad-hPON1 mice.
complex carries more negative charges than hPON1 in the mouse HDL complex.
Recombinant hPON1 associates with mouse HDL in vivo
To identify if Ad-hPON1-transduced recombinant hPON1 was capable of associating with mouse HDL, we performed non-denaturing PAGE analysis with purified hPON1, control mouse plasma and plasma from three Ad-hPON1-treated mice. Each of the plasma samples contained different hPON1 activity levels (942, 1656 and 2568 U ml -1 ). PON1 activity was identified by staining with b-napthyl acetate and Fast blue RR, while the presence of HDL in the samples was detected by using Sudan Black B. The results are illustrated in Figure 5 . The mouse plasma control shows a light band of diffuse PON1 activity with a diffuse band of HDL at the same gel location (lanes 1a and b). The purified hPON1 shows a diffuse band of PON1 activity with no corresponding HDL because the lipoprotein was removed during the purification process (lanes 2a and b). Plasma from the Ad-hPON1-treated mice showed broad diffuse bands of PON1 activity with intensities that correlate to the known activity levels ( Figure 5 , PON activity, lanes 4a, 5a, and 6a). Broad diffuse bands of HDL are observed in positions in the Sudan Black B-stained gel ( Figure 5 , Sudan Black, lanes 4b, 5b, and 6b) that correspond to the PON activity stained section. Similar results were obtained when these samples were processed on agarose gels (data not shown). These results show that the virus-transduced recombinant hPON1 associates with HDL in mouse plasma.
Protection of mice from OP toxicity by Ad-hPON1
We addressed the question of whether recombinant hPON1 expressed in mice at high levels would protect the animals from OP toxicity. As maximal PON1 levels were observed on days 3-5 post-treatment with Ad-hPON1, mice were challenged with diazoxon on day 4. Mice surviving the first dose of 28 mg kg -1 (2LD 50 dose) for 24 h were challenged again with another 2LD 50 dose of diazoxon and those that survived the second 2LD 50 dose for a minimum of 24 h received a third dose. Control mice (n¼3) and the treatment group (n¼6) were monitored for cholinergic symptoms following each dosing regimen. Surviving mice had cholinergic signs of toxicity only briefly. All signs of toxicity had disappeared by the time they were rechallenged with another dose of diazoxon. Observations of toxicity and time to death or morbidity are presented in Table 2 .
The Ad-hPON1-injected mice, on average, had sevenfold higher levels of PON1 activity on day 3 compared with day 0 (pre-AdhPON1). All three mice in the control group were moribund within 2 h of receiving the 2LD 50 dose. In contrast, all six mice of the treatment group survived the first 2LD 50 for 24 h. Four of the Ad-hPON1 mice survived a second 2LD 50 dose for 24 h and received a third 2LD 50 dose. The four animals receiving a total of 6LD 50 were moribund on average 20 min after receiving the last dose. PON1 levels in the two mice that were moribund after 4LD 50 were relatively lower (378 ± 67 U ml -1 ) than the levels in the four mice that received the third 2LD 50 dose (576±116 U ml -1 ). Overall, these results suggest that high levels of recombinant hPON1 in mice function as prophylactics that offer excellent protection against lethal doses of diazoxon. The protection level correlates with plasma PON1 levels. 1-3) for 30 min at room temperature before the gels were stained for esterase activity with b-naphthylacetate and Fast Blue RR. Lanes 1, 4, 7, 10 contain 1 ml human serum. Lanes 2, 5, 8, 11 contain 1 ml wild-type mouse serum (70 U ml -1 PON1 activity). Lanes 3, 6, 9, 12 contain 1 ml mouse plasma expressing 3482 U ml -1 of hPON1. A band for the butyrylcholinesterase (BChE) tetramer is near the top of the gel. PON1 makes a complex with high-density lipoprotein and migrates as a broad band. Carboxylesterase (CES) migrates just above albumin (ALB) in mouse plasma. Human plasma contains no carboxylesterase. (b) Gels were counter-stained with Coomassie blue to confirm the location of the albumin band.
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Sudan Black PON Activity Figure 5 PON1 activity and HDL in the plasma of control and adenovirustreated mice and in purified human PON1. Lanes 1a-6a were stained for PON1 activity with b-napthyl acetate. Lanes 1b-6b were stained for lipoproteins (HDL) with Sudan Black B. Lanes 1a and b contain control mouse plasma (1 ml) (70 U ml -1 ). Lanes 2a and b contain purified hPON1 (12.5 ml) (21 U ml -1 ). Lanes 3a and b are blank. Plasma (1 ml) from Ad-hPON1-treated mice are in lanes 4a and b (2568 U ml -1 ), 5a and b (942 U ml -1 ) and 6a and b (1656 U ml -1 ). Arrows point to the location recombinant hPON1-HDL complexes in both gels.
Observations made following the diazoxon challenge indicated that protection was afforded to the Ad-hPON1 treatment group. After the first 2LD 50 dose, the Ad-hPON1 group had no whole body tremors, reduced lacrimation, no splayed hind legs, no ataxic gait, no salivation and reduced piloerection ( Table 2) . Decrease in body temperature serves as a quantitative measure of toxicity. The average body temperature of the control group 2 h post-challenge or immediately before euthanasia was 30.2 ± 0.5 1C compared with 38.1 ± 0.7 1C measured at the same time in the Ad-hPON1-treated mice.
DISCUSSION
The hydrolytic activity of PON1 against certain OPs renders it an attractive therapeutic candidate for prevention and/or the treatment of toxicity from exposure to OP pesticides and nerve agents. As PON1 is a glycoprotein and optimally functional in complex with HDL, there are technical challenges and constraints in generating large quantities of robust PON1 for therapeutic evaluation and use. The results presented in this manuscript suggest that using adenoviral vectors to introduce PON1 into systemic circulation is a viable approach. Methods for delivering PON1 for protection against OP toxicity are summarized below.
Adenovirus
Our results show that (1) recombinant hPON1 clearly functions in prophylactic manner against OP toxicity when the levels in blood circulation are high and (2) PON1 has therapeutic potential as we were able to continually escalate the dose to 6LD 50 over a 3-day period. The PON1 activity levels in our studies were estimated to be up to 50-fold higher than the pre-adenovirus levels in some mice. A previous study using adenovirus to introduce hPON1 into mice reported a 60% increase in serum PON1 activity and prevention of toxicity 24 from chlorpyrifos as determined by inactivation of brain AChE levels. Studies addressing atherosclerosis through Ad-PON1 gene transfer were more successful, achieving 4-15-fold higher levels of PON1 in mice and improved vascular wall oxidative stress, endothelial cell function, smooth muscle cell Ca 2+ homeostasis and reduced oxidized LDL. 29, 30 Purified rabbit and hPON1 Protection by PON1 from OP toxicity has been achieved by injecting purified rabbit PON1 into rats and mice. By increasing the PON activity 30-to 50-fold above endogenous levels, rats and mice were protected from the toxicity of chlorpyrifos oxon as measured by inhibition of AChE activity. 21, 31 Treatment with purified rabbit PON1 30 min after poisoning mice with the phosphorothioate chlorpyrifos prevented all cholinergic signs of intoxication. 22 Engineered recombinant hPON1 containing the mutation K192 was expressed in Escherichia coli and purified. Post-treatment of PON1 knockout mice with the purified recombinant hPON1 protected the mice from the lethal effects of diazoxon. 16 A chimeric PON1 85% identical in amino-acid sequence to hPON1 was expressed in E. coli and used for protection experiments in mice. 32 It was found that the chimeric PON1 protected from the lethality of chlorpyrifos oxon.
Naked DNA Naked DNA injected into mice as a plasmid encoding hPON1 decreased the mortality from soman exposure. 33 Complex of recombinant hPON1 with mouse HDL Our results show that the hPON1 expressed by adenovirus in mice spontaneously associated with mouse HDL. These results have clear implications for analyzing the meaningful biological function(s) of any PON1 therapeutic testing, as such a complex formation is well known to be a pre-requisite for maintaining stable PON1 activity in serum. 34, 35 In addition, these results show that adenoviral gene transfer results in functional PON1-HDL complexes, without resorting to extraordinary genetic engineering means to generate such complexes. 32 A study which compared the effectiveness of pre-treatment with recombinant chimeric PON1 to pre-treatment with a PON1-HDL complex found that the recombinant chimeric PON1 Abbreviations: Ad-hPON1, adenovirus-expressing hPON1; hPON1, human paraoxonase1. a hPON1 activity was determined using phenylacetate as the substrate. Control mice received the Ad-control virus in the same manner as Ad-hPON1 mice.
on its own was more effective at protecting mice from chlorpyrifos oxon toxicity. It was hypothesized that upon intravenous administration, the recombinant chimeric PON1 associates with endogenous HDL particles that stabilize it and slow its clearance rate. 32 In this regard, while purified hPON1 was shown to associate with HDL when added to whole serum, 36 the fate of bacterially produced hPON1 injected into mice was not studied. 16 Our results not only provide direct evidence for such association between recombinant hPON1 and mouse HDL, but also show functional activity of such complexes.
Summary
We previously reported that gene transfer using adenovirus can be a promising strategy and can be effective for evaluating potential biological agents against chemical weapons in vivo. 37, 38 More recently, we found that these biological agents, namely truncated and fulllength human BChE and mouse BChE, protected mice from multiple LD 50 doses of the most toxic nerve agent VX and the pesticide echothiophate (Chilukuri et al., unpublished data). This study extends these results to PON1Q192 alloform, considered to be the most promising for pre-treatment in the category of catalytic bioscavengers against OP poisoning. We show that high levels of hPON1 delivered to mice through adenovirus means are highly effective in preventing OP toxicity. Excellent protection against lethal doses of diazoxon was notable as four of six mice survived 4LD 50 doses administered as two 2LD 50 doses 24 h apart. Moreover, the results show protection afforded to the treatment group in terms of a reduction in cholinergic signs of toxicity. Based on these results, we advocate continued investigations into gene transfer for thorough and systematic evaluation of PON1 as a prophylactic and therapeutic agent for possible military as well as civilian use. Current first generation adenoviral vectors may not be ideal for human use due to immunogenic or safety considerations. A safer gene delivery system approved for human use would deliver therapeutic levels of PON1 against OP and nerve agent poisoning. 
MATERIALS AND METHODS
Reagents and cells
Production of recombinant adenovirus-expressing hPON1
Recombinant Ad-hPON1 (gi:209413720 in the NCBI database) was generated as described in the applications manual (MP Biomedicals). Briefly, hPON1 cDNA (Q192 alloform) containing a 6Âhistidine tag at its carboxyl terminus was used in a polymerase chain reaction to introduce BglII restriction endonuclease sites at 5¢ and 3¢ ends of the gene. The primers used in the PCR reaction were 5¢-GAAGATCTATGGCGAAGCTGATTG-3¢ (forward) and 5¢-GAAGATCTTTACTAATGATGGTGATG-3¢ (reverse). The PCR product was cloned into adenoviral transfer vector, pAdenoVator-CMV5-IRES-GFP, linearized previously with restriction endonuclease BglII. The insert was fully sequenced to ensure that its nucleotide sequence was intact. The left and right arm of the pAdenoVator-CMV5-IRES-GFP vector contains Ad5 nucleotide sequences necessary to mediate homologous recombination with the Ad5dE1/dE3 vector in E. coli plus inverted terminal repeat and packaging signal sequences required for viral production in mammalian cells. For generation of recombinant adenovirus plasmids, pAdenoVator-CMV5-IRES-GFP-hPON1 plasmid was linearized with Pme1 and co-transformed with Ad5dE1/dE3 backbone plasmid into recombination proficient BJ5183 cells. Recombination was confirmed by Pac1 digestion and one of the recombined clones (pAd-hPON1) was retransformed into DH5a cells for large-scale plasmid preparation. For the production of recombinant Ad-hPON1 HEK-293A cells, which produce the deleted E1 genes in trans were transfected with 4 mg of Pac-1-digested pAd-hPON1 plasmid and Lipofectamine 2000. Cells were harvested 9 days post-transfection and re-suspended in Hanks Balanced Salt Solution and crude recombinant virus was collected after four freeze-thaw cycles. The low titer crude virus was sent to MP Biomedicals or Welgen Inc., Worcester, MA, USA for single clone selection, amplification, purification, viral titers and quality testing. Most in vitro assays were carried out with the Qbiogene/MP Biomedicals preparations and the in vivo experiments used the virus supplied by Welgen. The control adenovirus lacked the hPON1 cDNA, but was otherwise identical to the hPON1-expressing adenovirus.
Cell culture and infection with Ad-hPON1
HEK-293A cells (1Â10 6 ) were seeded in six-well plates. After 24 h, the cells were infected with 0-50 pfu of Ad-hPON1 for 1-2 h using 500 ml of infection medium (Dulbecco's modied Eagle's medium containing 2% FBS, antibiotics penicillin and streptomycin, and sodium pyruvate) at 37 1C. Following infection, 2.5 ml of growth medium (Dulbecco's modied Eagle's medium containing 10% FBS, 50 mg ml -1 penicillin and streptomycin, L-glutamine and 50 mg ml -1 sodium pyruvate) was added to the cells and incubated at 37 1C. The PON1 activity in the culture medium was quantified using paraoxon and phenyl acetate as the substrates. 19 In one experiment, hPON1 activity was quantitatively determined in the cell culture medium and lysate. Control virus and Ad-hPON1-infected cells on day 5 were lysed with 250 ml of M-per cell lysis reagent (Pierce Chemical Co., Rockford, IL, USA) and PON1 activity in cell culture medium and lysate was determined using phenyl acetate as the substrate. 18, 19 Partial purification of recombinant hPON1
HEK-293A cells (10Â10 6 ) were seeded in 150 cm 2 tissue culture dishes. After 24 h, the cells were infected with Ad-hPON1 (50 pfu per cell) for 1-2 h using 10 ml of infection medium at 37 1C. To the infected cells, 15 ml of growth medium was added and the cell cultures were incubated for 5-6 days when the activity of hPON1 levels peaked. The spent medium was collected and cleared of cell debris by centrifugation at 2500 rpm for 10 min at 4 1C. Partial purification of recombinant hPON1 was accomplished by subjecting the medium to ammonium sulfate fractionation followed by metal-affinity chromatography. Recombinant hPON1 from 100 ml of the culture medium was precipitated by raising the ammonium sulfate saturation from 50 to 80%. The precipitate was re-suspended and dialyzed against equilibration buffer (50 mM Tris-HCl pH 8.0, 2 mM CaCl 2 , 0.5 M NaCl). The dialysate was passed through a BD-Talon Cobalt-affinity resin column and the resin-bound recombinant hPON1 was eluted using equilibration buffer containing 500 mM imidazole and identified by western blot analysis.
Enzyme assays
The activity of PON1 was determined by using two substrates, paraoxon and phenylacaetate, to confirm that both esters are hydrolyzed by hPON1.
PON1 activity was measured with 1 mM paraoxon in a total volume of 800 ml of 50 mM glycine NaOH, 2 mM CaCl 2, pH 10.0. 20 The reaction was initiated by the addition of enzyme. Formation of the product, p-nitrophenol, was recorded as increase in absorbance at 412 nm at room temperature. The amount of p-nitrophenol produced was calculated using the molar extinction coefficient of 18 290 M À1 cm À1 . Blanks without enzyme were used to correct for spontaneous hydrolysis of paraoxon. One unit of paraoxonase activity is defined as 1 nmol of p-nitrophenol formed per min under the assay conditions. PON1 activity measured using phenylacetate as a substrate was determined as described previously. 20 Briefly, the cuvette contained 1 mM phenylacetate in 10 mM Tris-HCl, pH 8.0 and 2 mM CaCl 2 in a total volume of 2.0 ml. The reaction was initiated by the addition of enzyme. Formation of the product, phenol, was recorded as increase in absorbance at 270 nm at 25 1C. The amount of phenol was calculated according to the molar extinction coefficient of 1310 M À1 cm À1 . Blanks without enzyme were used to correct for spontaneous hydrolysis of phenylacetate. One unit of PON1 activity is defined as 1 mmol phenylacetate hydrolyzed per min under the above assay conditions.
Animal experiments
Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adhered to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 1996 Edition. All efforts were made to minimize animal suffering and to reduce the number of animals used for these studies. For these studies, adult female and male mice strain 129 Sv (20-25 g body weight) were housed at 20 1C and were provided food and water ad libitum.
Injection of Ad-hPON1 and Ad-control virus. On day 0, blood was collected from the saphenous vein before injection of mice with the recombinant (n¼8) or control virus (n¼8). Ad-hPON1 or Ad-control viruses were diluted in sterile saline to produce an inoculum of 4Â10 10 pfu in 150 ml of saline. The inoculum was injected rapidly via the tail vein in 5-10 s. Animals were observed for 30 min post-dosing for any untoward signs. Blood was collected for 10 days post-dosing via the saphenous vein into heparinized hematocrit tubes and centrifuged at 14 000 r.p.m. for 10 min at 4 1C. The plasma was removed and assayed for PON1 activity with paraoxon and phenylacetate or stored at À80 1C for use in further studies.
Determination of PON1 levels in the tissue of virus-injected mice. In one experiment, two Ad-hPON1-and one Ad-control virus-injected animals were euthanized on day 4 post-virus injection. The animals were perfused with 50 ml of 0.1 M phosphate-buffered saline before their liver, lung, heart, brain, kidney, muscle, intestine, stomach, skin, testes, spleen, diaphragm, salivary glands and fat were removed and flash frozen. Tissues were homogenized in ice cold buffer containing 50 mM potassium phosphate pH 7.4, 0.5% Tween 20 and centrifuged at 12 000 r.p.m. for 10 min at 4 1C. The supernatants were removed into clean tubes and assayed for PON1 activity with phenylacetate.
Determination of LD 50 of diazoxon in strain 129 Sv mice. Diazoxon (C12H21N2O4P) is the oxon version of pesticide diazenon (C12H21N2O3PS), usually formed in the body by microsomal oxidation of P¼S to P¼O bond. As LD 50 values depend on the mouse strain, we determined the LD 50 of diazoxon by treating adult strain 129 Sv mice with various doses of diazoxon dissolved in ethanol. The LD 50 value was found to be 14 mg kg -1 injected subcutaneously.
Challenge with diazoxon. Ad-hPON1 (n¼6) and Ad-control (n¼3) were injected into the tail vein of mice as described above. Plasma was collected from all the mice before viral injection and daily through day 4 post-viral injection. PON1 activity was assayed with phenylacetate. On day 4 post-viral injection baseline temperature, body weights and observations were recorded. Mice were challenged subcutaneously with 2LD 50 of diazoxon (28 mg kg -1 ). Mice were observed continuously through 1-h post-challenge. Axial body temperatures and signs of cholinergic toxicity were recorded hourly through 7 h post-challenge. Moribund mice were euthanized immediately. Animals that survived the first 2LD 50 challenge were challenged with another 2LD 50 24 h after the first challenge. The same procedures were followed during the second challenge. Animals that survived 4LD 50 were injected 24 h later with another 2LD 50 following the same procedures.
Sodium dodecyl sulfate-PAGE and western blotting
Sodium dodecyl sulfate-PAGE was carried out with precast 10% gels. After electrophoresis, the proteins were transferred to PVDF membrane. The membrane was blocked in 4% powdered milk for 1 h, washed once with Tris-buffered saline containing Triton X-100 (TTBS) and incubated overnight in primary antibody (anti-6Âhistidine antibody, 1:1000 dilution or rabbit polyclonal antibody to recombinant hPON1, 1:2000 dilution) in 0.5% milk powder containing 0.01% sodium azide. The membrane was washed with TTBS five times with intermittent shaking for 8 min and incubated with a secondary antibody conjugated with Horse Radish Peroxidase (100 ng ml -1 ) in 0.5% milk powder for 1 h. The membrane was washed again as above and the protein bands detected using ECL-Plus reagent. Chemiluminescence was measured in a Bio-Rad image reader.
Non-denaturing PAGE for esterase activity PON1 activity in mouse plasma was visualized on non-denaturing polyacrylamide gradient gels (4-30%) stained for esterase activity. Plasma samples were mixed with 10 volumes of 25% glycerol, 0.05 M Tris-Cl, pH 7.5, 0.05% bromophenol blue before loading on the gel. The equivalent of 1 ml of plasma from an Ad-PON1-injected mouse, 1 ml of human serum and 1 ml of wild-type mouse plasma was loaded per lane. Gels were run for 5000 V h at 4 1C. The staining for PON1 activity was adopted from methods described before. 39, 40 The staining solution contained 100 ml of 50 mM Tris-Cl, pH 7.4, 10 mM calcium chloride, 50 mg of b-naphthylacetate dissolved in 1 ml of ethanol and 50 mg of solid Fast Blue RR. Undissolved naphthylacetate and Fast Blue RR are present, but do not interfere with color development. Reactive enzyme was identified by pink bands. After 20-60 min, the gel was washed with water; spots of solid reagents were washed off with 50% methanol, 10% acetic acid.
Plasma contains multiple esterases including PON1, BChE, CES and ALB. To distinguish between them, gels were preincubated for 30 min with 0.2 mM DFP or 0.2 mM diazoxon to inhibit BChE and CES, or with 10 mM EDTA to inhibit PON1 before they were stained with b-naphthylacetate and Fast Blue RR. The ALB band was identified by counter-staining the gels with Coomassie blue.
Non-denaturing PAGE for PON1 activity and HDL
A non-denaturing polyacrylamide gel (4-30%, 0.75 mm) loaded with duplicate samples was run for 3200 V h. Mouse plasma (1 ml) with no expressed Ad-hPON1 (70 U ml -1 ) was compared with plasma from mice (1 ml) expressing Ad-hPON1 (2568, 942 and 1656 U ml -1 ). Purified hPON1 containing no associated HDL was run as a control (purified hPON1 was a gift from Mrs Frederique Renault and Dr Daniel Rochu, IRBA-CRSSA, La Tronche, France). PON1 activity in the gels was identified by staining one section of the gel with b-napthyl acetate and Fast blue RR. Activity was shown by the presence of diffuse purple bands. The presence of HDL in the samples was detected by staining the gel section overnight in Sudan Black B (Sigma, St Louis, MO, USA), a dye that detects lipoproteins. 41 
